secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001062822-26-000094
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon secures $100M loan facility from Hercules Capital; $55M funded at closing
--------------------------------------------------------------------------------

- Initial $55M tranche drawn at closing to repay existing Oxford Finance loan; second $20M and third $25M tranches available subject to milestones.
- Interest rate = prime + 3.10% with 9.85% floor; initial 18-month interest-only period extendable to 30 months upon achieving clinical/regulatory milestones.
- Loan matures May 4, 2030; secured by first lien on all assets; minimum cash covenant starts June 1, 2027.
- Hercules received warrants to buy 691,823 shares at $1.59 per share; additional warrants up to 566,037 shares upon future tranche draws.
- Funds support Lexicon's late-stage cardiometabolic pipeline including sotagliflozin HCM trial and potential regulatory filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/0001062822-26-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282226000094/lxrx-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001062822-26-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer